retatrutide phase 3 results october 2025 Today, we shared new data from two trials of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Eli Lily’s Retatrutide 💊 Phase

We also ensure patients with contraindications, such as severe kidney disease or thyroid cancer, are fully informed

You just need it spread out

Rather than dismissing or criticizing patients for their choices, clinicians should objectively evaluate potential risks, verify exactly what the patient is taking, and develop a safe, evidence-based treatment plan that preserves trust while strengthening the therapeutic relationship

As anticipated, PSD95 immunoreactivity was uniformly observed as small puncta across the mouse brain, but not in tissues devoid of synapses such as the anterior pituitary gland and the liver (Supplementary Fig

The survey was conducted April 23-May 1, 2024, online and by telephone among a nationally representative sample of 1,479 U.S